Santen SAS

An Introduction to NAYA Biosciences with CEO Dr. Daniel Teper Managing unprecedented medical innovation in an era of financial market volatility Increasing patient access to breakthrough treatments in oncology, regenerative medicine, and fertility SARASOTA, Fla. and AVENTURA, Fla., Oct. 27, 2023 /PRNewswire/ -- INVO Bioscience ("INVO") and NAYA Biosciences ("NAYA"), two companies which recently signed a definitive merger agreement, today announced that NAYA CEO Dr. Daniel Teper will present at Tribe Public's Webinar Presentation and Q&A Event, titled "Accelerating Biotech Value Creation" . The event is scheduled to begin at 8:30AM PST/11:30AM EST on Tuesday, October 31, 2023. To register to join the complimentary event, please visit the Tribe Public LLC at NAYAOCT3123.TribePublic.com. Continue Reading Free Registration Is Now Open For Tribe Public’s CEO and Q&A Presentation Webinar Event "Accelerating Biotech Value Creation" Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023 NAYA Biosciences Inc. (PRNewsfoto/INVO Bioscience, Inc.) NAYA Biosciences is building a group of agile, disruptive, high-growth companies dedicated to increasing patient access to life-transforming treatments in oncology, fertility, and regenerative medicine. NAYA's capabilities in biology, cell and gene therapy, and artificial intelligence (AI) provide a synergistic platform for the accelerated clinical development and commercialization of these breakthrough treatments. Dr. Teper is the Founder, Chairman, and Chief Executive Officer of NAYA Biosciences. He has over 30 years of leadership experience as a biopharma entrepreneur, corporate executive, and management consultant. Previously, Dr. Teper was the Chairman & CEO of Cytovia Therapeutics, where he remains Chairman of the Board. From 2011 to 2017, he was the CEO of Immune Pharmaceuticals, which he listed on NASDAQ. He previously served as New York-based Managing Partner (Head of North America) at Bionest Partners, now Accenture, where he advised companies on corporate strategy and business development. He was previously a Partner at ISO Healthcare Group, now Deloitte, in New York. Dr. Teper helped drive the accelerated growth of Softwatch, a pioneer digital health company, as senior vice president of sales and business development. He also served as global president of Havas Health, advising companies on global launches of major new drugs in multiple disease areas. Dr. Teper started his career at Novartis in Basel and then in the US, where he held management responsibilities in sales and marketing and as head of cardiovascular, new product development. Dr. Teper held general management positions in Europe at GlaxoSmithKline and Sanofi. He was the co-founder and CEO of Wintec Pharma, a European specialty pharmaceutical company focused on anti-infectives and dermatology, which he went on to sell. Dr. Teper co-founded Novagali, an ophthalmology specialty pharma later listed on EuroNext Paris and acquired by Japan's Santen.He holds a Doctor of Pharmacy degree from Paris XI University and an MBA from INSEAD, where he was the J. Salmon scholar. Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at [email protected] or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management. ABOUT NAYA Biosciences NAYA Biosciences is building a group of agile, disruptive, high-growth companies dedicated to increasing patient access to life-transforming treatments in oncology, fertility, and regenerative medicine. NAYA's capabilities in biology, cell and gene therapy, and artificial intelligence (AI) provide a synergistic platform for the accelerated clinical development and commercialization of these breakthrough treatments. NAYA Oncology aims to achieve clinical proof-of-concept for its two bispecific antibodies acquired from Cytovia Therapeutics, with the goal of advancing towards breakthrough outcomes for Hepatocellular Carcinoma and Multiple Myeloma patients. Clinical trials are expected to start in 2024. NAYA Fertility aims to increase accessibility to advanced fertility care through a growing network of INVO-owned and affiliated clinics and the commercialization of INVO's unique FDA-cleared INVOcell® device. NAYA Regenerative Medicine is evaluating the acquisition of clinic-stage assets aiming to restore biological function in patients with damaged tissues and organs. For more information, please visit . About INVO Bioscience We are a healthcare services fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell® and IVC procedure (with three centers in North America now operational), the acquisition of US-based, profitable in vitro fertilization ("IVF") clinics and the sale and distribution of our technology solution into existing fertility clinics. Our proprietary technology, INVOcell®, is a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. We believe the IVC procedure can deliver comparable results to traditional IVF and is a more effective treatment than intrauterine insemination ("IUI"). For more information, please visit . ABOUT TRIBE PUBLIC LLC Tribe Public LLC is a San Francisco, CA based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe's complimentary events focus on issues that the Tribe members care about with an emphasis on hosting management teams from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress and plans. Tribe members primarily include Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe Members are encouraged to express their interest in speakers they care about and want to learn from at the Tribe Public website via the Tribe's FREE "Wish List" process. Visit Tribe Public's Website to learn more: Additional Information about the Proposed Merger and Where to Find It INVO filed a current report on Form 8-K with the U.S. Securities and Exchange Commission (the "SEC") regarding the Merger, which included the Merger Agreement as an exhibit thereto. Closing of the merger remains subject to key closing conditions as defined in the merger agreement, including shareholder approval. Shareholders and others wishing to obtain additional information regarding the Merger Agreement and the Merger are urged to review these documents, which are now available at the SEC's website (). Safe Harbor Statement This release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. INVO invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding INVO's expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond INVO's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in INVO's filings at . INVO is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. SOURCE INVO Bioscience, Inc.

Los Angeles, June 10, 2021 (GLOBE NEWSWIRE) -- Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight The majority of the drugs for Corneal Ulcer are in the early stages of development and in coming years the market is expected to grow. DelveInsight’s ‘Corneal Ulcer Pipeline Insights’ report provides the current treatment landscape and rich analysis of pipeline therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents. Some of the key pointers from the Corneal Ulcer Pipeline report: Discover more about the pharma company and therapy expected to grab maximum share by requesting sample report @ Corneal Ulcer Emerging Therapies and Forecast Corneal Ulcer: Overview Corneal Ulcer, also known as Keratitis, is characterized by damage or loss of the epithelial layer associated with infiltration of the underlying corneal stroma. Whilst the treatment of refractory corneal ulcers is challenging, it is essential that they are resolved as they can quickly endanger the anatomical integrity of the ocular surface or the transparency of the cornea. Discover more about disease outlook, available therapies, and emerging drugs, visit Corneal Ulcer Pipeline Analysis Corneal Ulcer Drug Pipeline Assessment Request for Sample to know more @ Corneal Ulcer Pipeline Analysis, Key Companies, and Futuristic Trends Corneal Ulcer Therapeutics Assessment The Corneal Ulcer Pipeline report lays down a comprehensive coverage of the active pipeline candidates segmented by Stage, Product Type, Route of Administration (RoA), Molecule Type, Target, and Mechanism of Action (MoA). By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets Connect with our Business Executive for Asset Prioritization Services and Consulting Solutions Scope of the Corneal Ulcer Pipeline Report Coverage: GlobalKey Players: Recordati/Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, OcuNexus Therapeutics, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc., Dobecure, Editas medicine, and others. Key Corneal Ulcer Pipeline Therapies: REC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium, and others. Reach out @ Corneal Ulcer Pipeline: Novel therapies and Emerging technologies Table of Contents Learn more about the report offerings @ Corneal Ulcer Emerging Therapies, Treatments and Ongoing Clinical Trials Related ReportsCorneal Ulcer MarketDelveInsight's "Corneal Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report.Peptic Ulcer Hemorrhage MarketDelveInsight's "Peptic Ulcer Hemorrhage - Market Insights, Epidemiology, and Market Forecast-2030" report.Varicose Ulcer MarketDelveInsight's " Varicose Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report. Venous Leg Ulcer MarketDelveInsight's "Venous Leg Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report. Related Posts Global Burden of Cytomegalovirus SeroprevalenceAnalysis of therapies and key companies such as Merck, Helocyte, Shire, Atara Biotherapeutics, ViraCyte, and others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News